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Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP
signaling, is inhibited by TSC1 and 2
Abstract
Tumor suppressor genes evolved as negative effectors of mitogen and nutrient signaling pathways, such
that mutations in these genes can lead to pathological states of growth. Tuberous sclerosis (TSC) is a
potentially devastating disease associated with mutations in two tumor suppressor genes, TSC1 and 2,
that function as a complex to suppress signaling in the mTOR/S6K/4E-BP pathway. However, the
inhibitory target of TSC1/2 and the mechanism by which it acts are unknown. Here we provide evidence
that TSC1/2 is a GAP for the small GTPase Rheb and that insulin-mediated Rheb activation is PI3K
dependent. Moreover, Rheb overexpression induces S6K1 phosphorylation and inhibits PKB
phosphorylation, as do loss-of-function mutations in TSC1/2, but contrary to earlier reports Rheb has no
effect on MAPK phosphorylation. Finally, coexpression of a human TSC2 cDNA harboring a
disease-associated point mutation in the GAP domain, failed to stimulate Rheb GTPase activity or block
Rheb activation of S6K1.
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Insulin Activation of Rheb,
a Mediator of mTOR/S6K/4E-BP Signaling,
Is Inhibited by TSC1 and 2
which in rare cases progress to renal cell carcinomas
(Young and Povey, 1998). The contribution of TSC1/2
mutations to cancer progression may be much more
prevalent than noted, as one in six thousand individuals
is born with a mutation in either TSC1 or 2 (Montagne
Attila Garami,1,4 Fried J.T. Zwartkruis,2,4
Takahiro Nobukuni,1 Manel Joaquin,1
Marta Roccio,2 Hugo Stocker,3
Sara C. Kozma,1 Ernst Hafen,3
Johannes L. Bos,2 and George Thomas1,*
et al., 2001; Sparagana and Roach, 2000). Consistent1Friedrich Miescher Institute
with this, studies in Drosophila and in mammals demon-for Biomedical Research
strate that TSC1/2 acts to constrain both mitogen- andMaulbeerstrasse 66
nutrient-induced activation of the mTOR/S6K/4E-BP4058 Basel
signal transduction pathway (Marygold and Leevers,Switzerland
2002; McManus and Alessi, 2002), which has been impli-2 Department of Physiological Chemistry and
cated in the progression of a number of solid tumorsCentre for Biomedical Genetics Universiteitsweg
(Abraham, 2002; Hidalgo and Rowinsky, 2000; Sekulic100 3584 CG Utrecht
et al., 2000). At least in part, TSC1/2 repression of theThe Netherlands
mitogen-induced segment of the mammalian mTOR/3 Zoologisches Institut der Universita¨t Zu¨rich
S6K/4E-BP signaling pathway appears to be relievedWinterthurerstrasse 190
by protein kinase B (PKB) phosphorylation of TSC2, a8057 Zu¨rich
response mediated by insulin-induced activation ofSwitzerland
phosphatidylinositide-3OH kinase (PI3K) (Goncharova
et al., 2002; Inoki et al., 2002; Jaeschke et al., 2002;
Manning et al., 2002). Moreover, hamartomatous lesionsSummary
are also observed in patients with one of three related
autosomal-dominant disorders associated with germ-Tumor suppressor genes evolved as negative effectors
line mutations in PTEN, a negative effector of PI3K: Cow-of mitogen and nutrient signaling pathways, such that
den disease (CD), Lhermitte-Duclos disease (LDD), andmutations in these genes can lead to pathological states
Bannayan-Zonana syndrome (BZS) (Liaw et al., 1997).of growth. Tuberous sclerosis (TSC) is a potentially dev-
However, unlike the case in PTEN, the exact mechanismastating disease associated with mutations in two tu-
by which TSC1/2 represses mTOR/S6K/4E-BP signalingmor suppressor genes, TSC1 and 2, that function as
is unknown, as is the identity of the inhibitory target.a complex to suppress signaling in the mTOR/S6K/4E-
The severest forms of TSC syndrome are associatedBP pathway. However, the inhibitory target of TSC1/2
with mutations that map to the GTPase activating do-and the mechanism by which it acts are unknown.
main of TSC2 (Maheshwar et al., 1997 and D. Franz,Here we provide evidence that TSC1/2 is a GAP for the
personal communication). Consistent with TSC2 func-small GTPase Rheb and that insulin-mediated Rheb
tioning as a GTPase activating protein (GAP), it had beenactivation is PI3K dependent. Moreover, Rheb overex-
reported that the GTPase activity of Rap1, a member ofpression induces S6K1 phosphorylation and inhibits
the Ras superfamily of small GTPases, is stimulatedPKB phosphorylation, as do loss-of-function muta-
in vitro by TSC2 (Wienecke et al., 1995). However, wetions in TSC1/2, but contrary to earlier reports Rheb
previously found that insulin had no effect on Rap1 activ-has no effect on MAPK phosphorylation. Finally, coex-
ity in cells overexpressing the insulin receptor (Zwart-pression of a human TSC2 cDNA harboring a disease-
kruis et al., 1998), while potently activating S6K1 in theseassociated point mutation in the GAP domain, failed
same cells (Ming et al., 1994). To identify potential
to stimulate Rheb GTPase activity or block Rheb acti-
GTPases as targets of TSC2 GAP, we set out to deter-
vation of S6K1. mine whether the activity of any Ras superfamily mem-
ber (Bos, 1997) was elevated in TSC2/ versus TSC2/
Introduction mouse embryo fibroblasts (MEFs). From such studies,
Rheb (Ras homologue enriched in brain) emerged as a
Tuberous sclerosis (TSC) syndrome is an autosomal- possible candidate. In parallel, a role for Rheb in the
dominant genetic disorder, characterized by mutations mTOR/S6K/4E-BP signaling pathway became apparent
in either the TSC1 or TSC2 gene, whose protein products from genetic studies in Drosophila (see Discussion).
hamartin (TSC1) and tuberin (TSC2) form a putative tumor Rheb was first identified in a differential screen of
suppressor complex (Montagne et al., 2001; Sparagana mRNAs induced in neurons by agents that provoke sei-
and Roach, 2000). TSC can cause severe pathological zures (Yamagata et al., 1994) and is ubiquitously ex-
consequences, including mental retardation, epilepsy, pressed, but particularly abundant, in muscle and brain
and autism as well as leading to cardiac, pulmonary, (Yamagata et al., 1994). Moreover, Rheb was shown to
and renal failure (Montagne et al., 2001; Sparagana and have intrinsic GTPase activity (Yamagata et al., 1994)
Roach, 2000). These pathological states arise from ha- and to be as efficient as wild-type Raf-1 or H-Ras in
martomas, largely manifested as benign tumors, but inducing transformation in NIH3T3 cells (Yee and Wor-
ley, 1997). Importantly, in S. pombe deletion of the Rheb
ortholog, Rhb1, affects amino acid transport and nutri-*Correspondence: gthomas@fmi.ch
4These authors contributed equally to this work. ent sensing (Mach et al., 2000), as has been recently
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shown for the deletion of the S. pombe TSC1/2 orthologs showed a striking elevation in the levels of GTP bound
Rheb in extracts of TSC2/ as compared to TSC2/tsc1 and 2 (Matsumoto et al., 2002). Moreover, recent
MEFs, in contrast to what was observed for the otherstudies in S. cerevisiae have potentially created a link
Ras-like GTPases (Figure 1B). These findings would fitbetween Rheb and Batten disease, an autosomal-reces-
a model whereby TSC1/2 functions as a GAP for Rheb.sive neurodegenerative disorder that is associated in
To test this possibility further, myc epitope-tagged Rhebmany cases with deletions in the human CLN3 gene, a
was ectopically expressed in COS cells with either HAtransmembrane protein of unknown function (see Coo-
epitope-tagged TSC1 or HA epitope-tagged TSC2 aloneper, 2003). In brief, earlier studies showed that deletion
or with both tumor suppressors together, and the ratioof the CLN3 ortholog, BTN1, in S. cerevisiae leads to
of GTP to GDP bound Rheb was determined. The resultsthe upregulation of only two genes, HSP30 and BTN2,
show that coexpression of TSC1 had no effect on thethought to be involved in regulating vacuolar pH (Pearce
amount of Rheb in the GTP bound form, whereas coex-et al., 1999). Recently, BTN2 was employed as bait in a
pression of TSC2 alone lowered these levels, an effectyeast two-hybrid screen, which led to the identification
which was strongly potentiated by TSC1 (Figure 1C). Itof the S. cerevisiae ortholog of Rheb, RSG1, as a positive
should be noted that basal ratio of GTP to GDP wasinteracter (Chattopadhyay et al., 2003). More impor-
always high when ectopically expressing Rheb, consis-tantly, it was shown that the two protein products of
tent with the findings reported by Im et al. (Im et al.,the BTN2 and RSG1 genes, Btn2p and Rsg1p, interact
2002 and see Discussion). The specificity of TSC1/2-biochemically and genetically to control amino acid up-
GAP was controlled by coexpression of HA epitope-take (Chattopadhyay et al., 2003). Given the role of amino
tagged Rap1-GAP (RG), a known GAP for Rap GTPaseacids and nutrients in mTOR/S6K/4E-BP signaling (Den-
family members, which had no effect on the Rhebnis et al., 1999; Schmelzle and Hall, 2000) and the associ-
GTPase activity (Figure 1D). Likewise, coexpression ofation of TSC1/2 mutations in neurological disorders, we
TSC1/2-GAP with HA epitope-tagged Rap2 led to nowere further prompted to query whether Rheb could
measurable change in GTP bound Rap2, whereas coex-serve as the inhibitory target of TSC1/2.
pression of RG with Rap2 greatly lowered these levelsHere, we identified Rheb as a potential GTPase target
(Figure 1D). Taken together, these findings support aof TSC1/2-GAP by screening Ras superfamily members
model whereby TSC1/2 functions as a GAP for Rheb,for elevated GTPase activity in TSC2/ MEFs. Next, we
such that loss of TSC1/2-GAP function leads to in-determined whether TSC1/2 functions as a Rheb-GAP
creased levels of activated Rheb.and whether insulin activates Rheb. In parallel, we tested
Insulin-induced activation of PI3K relieves TSC1/2 re-whether ectopic expression of Rheb induces S6K1 acti-
pression of the mTOR/S6K/4E-BP signaling pathwayvation and whether insulin-induced S6K1 stimulation is
(Jaeschke et al., 2002). If the inhibitory target of TSC1/2dependent on Rheb. Finally, we analyzed whether Rheb
is Rheb, then insulin treatment should increase themediated activation of S6K1 is affected by a pathologic
amount of GTP bound Rheb, which should be blockedmutation in human TSC2, which fails to inhibit S6K1
by the PI3K inhibitor wortmannin, but resistant to theactivation.
mTOR inhibitor rapamycin. To examine this possibility,
Rheb was immunoprecipitated from [32P]-labeled, se-
rum-starved A14 NIH 3T3 cells that were stimulated forResults
30 min with insulin alone or in the presence of either
wortmannin or rapamycin. The ratio of GTP to GDPIf the effects of TSC1/2 loss of function mutations are
bound Rheb was then determined by one-dimensionalmediated by an increase in the GTP bound form of a
thin-layer chromatography. As a control, the activationRas small GTPase superfamily member, then a higher
of Ras was followed in parallel. The results show thatproportion of this form should be detected in TSC2/
insulin induces an approximate 2-fold increase in the
MEFs, as compared to TSC2/MEFs. To test this possi-
amount of GTP bound Ras and Rheb (Figure 2A), with
bility, we screened extracts from serum-deprived
the fold increase in GTP bound Rheb being 1.8  0.11
TSC2/ and TSC2/ MEFs employing activation-spe- SEM, averaged over three independent experiments.
cific probes, in which GTP bound Ras-like GTPases are Moreover, the insulin-induced increase in GTP bound
specifically isolated using GST-fusion proteins con- Rheb, but not that of Ras, is blocked by wortmannin,
taining the downstream GTPase target proteins (van whereas both increases are resistant to rapamycin (Fig-
Triest et al., 2001). The results of such an assay show ure 2A). That the effects of wortmannin are through PI3K
that there was no difference in the level of Ras, Rap2, and that rapamycin blocks mTOR signaling are sup-
or Ral bound GTP in the two cell types (Figure 1A). In ported by the fact that in parallel cultures treated in
parallel, we also attempted to pull down Rheb employing the identical manner, except for the omission of [32P]-
these same probes, including a GST-fusion protein that orthophosphate, insulin-induced PKB S473 and S6K1
contains the Ras binding domain of Raf1 (GST-RBD). T389 phosphorylation are blocked by the PI3K inhibitor,
However, these findings were inconclusive, most likely whereas only rapamycin inhibits S6K1 T389 phosphory-
due to the low affinity of Rheb for the various fusion lation (Figure 2B). Furthermore, neither wortmannin nor
proteins as a consequence of the markedly divergent rapamycin affects MAPK phosphorylation (Figure 2B),
effector region of Rheb (Bos, 1997). Therefore, Rheb consistent with the fact that neither inhibitor has an
was immunoprecipitated from either [32P]-labeled, se- effect on Ras activation (Figure 2A). These data are
rum-starved TSC2/ MEFs or TSC2/ MEFs, and the compatible with insulin-induced activation of PI3K re-
ratio of GTP to GDP bound Rheb was determined by lieving TSC1/2-GAP inhibition of Rheb, which in turn
leads to activation of the mTOR/S6K/4E-BP signalingone-dimensional thin-layer chromatography. The result
TSC1/2: A GAP for the Small GTPase Rheb
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Figure 1. TSC1/2 Exhibit GAP Activity to-
ward the Ras-like Small GTPase Rheb
(A) TSC2 does not affect the activity of the
Ras superfamily member Ras, Rap2, and Ral
small GTPases. The active, GTP bound form
of the indicated endogenous small GTPase
was specifically pulled down from serum-
deprived TSC2/ and TSC2/MEFs and vis-
ualized by immunobloting. TL, total lysate;
PD, pull-down.
(B) Loss of TSC2 function leads to elevated
levels of GTP bound Rheb. Endogenous Rheb
from serum-deprived [32 P]-orthophospate la-
beled TSC2/ and TSC2/MEFs was immu-
noprecipitated, and the ratio of GTP to GDP
bound Rheb was determined by Phospho-
Imager analysis following one-dimensional
thin-layer chromatography.
(C) TSC1/2 exhibit GAP activity toward Rheb.
COS-7 cells were transfected with 2 ug of
TSC1, TSC2, Rap1GAP (RG), and Rheb as
indicated, and after immunoprecipitation the
amount of GTP versus GDP was measured
as in (B).
(D) The GTPase activity of Rap2 is not stimu-
lated by TSC2. The experiment was per-
formed as in (C), except that Rap2 was trans-
fected and assayed.
pathway. If Rheb acts downstream of insulin, then Rheb MAPK activation, as judged with a phosphospecific anti-
body (Figure 3A). This finding is consistent with ouroverexpression alone might be expected to activate the
mTOR/S6K/4E-BP signaling pathway, especially as un- inability to pull down Rheb with the Ras binding domain
from Raf1 in the activation-specific probe assay and withder these conditions it is largely in the activated GTP
bound form (Figure 1C and data not shown). To test this insulin-induced MAPK activation being independent of
the GTP bound status of Rheb (Figures 2A and 2B). Losspossibility, myc epitope-tagged S6K1 was coexpressed
with Rheb, in the absence or presence of insulin. Coex- of TSC1/2 function also leads to constitutive 4E-BP1
phosphorylation and the suppression of both basal andpression of Rheb alone induced S6K1 activation to a
higher extent than that achieved by insulin stimulation, insulin-stimulated PKB activation (Jaeschke et al.,
2002). As 4E-BP1 is a second target of mTOR kinaseas determined by increased S6K1-T389 phosphorylation
(Figure 2C). Likewise, coexpression of Rheb alone also (Brunn et al., 1997; Gingras et al., 1998), it led to the
hypothesis that TSC1/2 functions through inhibitinginduced S6K2 activation in the absence of mitogen stim-
ulation (Figure 2D). Thus, consistent with the model and mTOR (see Discussion), whereas the effects on PKB
may be mediated by S6K1 through a negative feedbackTSC1/2 loss of function mutations (Jaeschke et al.,
2002), overexpression of Rheb drives constitutive acti- loop, as recently demonstrated in Drosophila (Radimer-
ski et al., 2002). To examine the effect of Rheb on 4E-vation of S6K1 as well as S6K2.
Despite the observations above, recent studies have BP1 and PKB, both proteins were ectopically expressed
with an HA epitope-tag. Coexpression of Rheb with 4E-implicated Rheb as a negative effector of Ras signaling
through competing with Ras for binding to B Raf, BP1 led to constitutive phosphorylation of 4E-BP1 in
the absence of insulin, as judged by 4E-BP1 T70 phos-blocking subsequent activation of MEK and MAPK (Im
et al., 2002). However, loss of TSC1/2 function has no phorylation, an effect not enhanced by insulin (Figure
3B). In parallel, coexpression of Rheb effectively lowersapparent effect on MAPK activation (Jaeschke et al.,
2002). To evaluate the effect of Rheb on Ras/MAPK both basal- and insulin-induced PKB S473 phosphoryla-
tion, without affecting PKB/Akt protein levels (Figuresignaling, HA epitope-tagged p44 MAPK was coex-
pressed with myc epitope-tagged Rheb in HeLa cells. 3C). These findings support the hypothesis that insulin-
induced activation of the mTOR/S6K/4E-BP signalingThe results show that expression of Rheb alone or in
the presence of serum had no apparent effect on p44 pathway is mediated by Rheb. To test this possibility,
Molecular Cell
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Figure 2. Insulin Induces Rheb Activation, and Ectopic Expression of Rheb Activates S6K1 and 2
(A) Insulin-induced activation of PI3K relieves TSC1/2 GAP mediated inhibition of Rheb. Serum-deprived A14 NIH 3T3 cells were incubated
with [32P]-orthophosphate for 4–6 hr and then treated with 200 nM insulin alone or in the presence of 100 nM wortmannin or 20 nM rapamycin
as indicated. Endogenous Rheb or Ras were pulled down and assayed as in Figure 1B.
(B) Insulin-induced phosphorylation of PKB, S6K1, and MAPK. Cells were treated as in (A), except for the omission of [32P]-orthophosphate,
and the phosphorylation of PKB, S6K1, and MAPK was followed with phoshospecific antibodies to each protein.
(C) Ectopic expression of Rheb activates S6K1. Myc-S6K1-GST was transiently expressed in HeLa cells alone or together with myc-Rheb.
After overnight serum deprivation cells were stimulated with 200 nM insulin as indicated, and phosphorylation of the kinase was detected
with a phosphospecific antibody.
(D) Rheb constitutively activates S6K2 in the absence of insulin. HeLa cells were transfected with S6K2-GST alone or together with myc-
Rheb. S6K2 activity was assayed as described in (C).
siRNAs were generated against Rheb and tested for fects of wortmannin were shown to go through PI3K, as
dominant interfering alleles of the p85 and p110 subunitstheir ability to suppress insulin-induced activation of
S6K1. The results of such an experiment show that two of PI3K blocked S6 phosphorylation in TSC2/ MEFs,
but not in TSC2/ MEFs (Jaeschke et al., 2002). Thesedifferent siRNAs against Rheb inhibit S6K1 T389 phos-
phorylation to approximately the same extent to which effects have been argued to go through PKB, although
not all agonists which activate S6K1 activate PKB (Radi-they lower Rheb expression levels, whereas a control
siRNA, known to have no effect on Rheb levels, has merski and Thomas, 2003). If the effects of wortmannin
and rapamycin on the TSC2 loss-of-function phenotypeno effect on S6K1 activation (Figure 3D). Thus, Rheb
appears to mediate insulin-induced activation of the are mediated by Rheb, similar effects of the two inhibi-
tors would be expected on Rheb-induced S6K1 activa-mTOR/S6K/4E-BP signaling pathway, rather than acting
in the Ras/MAPK pathway. tion. The results of this experiment reveal that wortman-
nin has little effect on Rheb-induced S6K1 activation,As compared to TSC2/MEFs, TSC2/MEFs exhibit
constitutive S6K1 activity, which is largely resistant to whereas it totally abolishes the insulin response (Figure
4A). In contrast, rapamycin ablates both Rheb- and insu-inhibition by wortmannin, but which remains rapamycin
sensitive (Figure 4A and Jaeschke et al., 2002). The ef- lin-induced S6K1 activation (Figure 4A), similar to what
TSC1/2: A GAP for the Small GTPase Rheb
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Figure 3. Effect of Ectopic Expression of Rheb and Rheb siRNA on Insulin-Induced Signaling Components
(A) Rheb has no effect on MAPK activity. HeLa cells were transfected with HA epitope-tagged p44 MAPK alone or together with myc epitope-
tagged Rheb. Serum-deprived cells were stimulated with 10% fetal calf serum for 30 min as indicated, and p44 MAPK phosphorylation was
detected with a phosphospecific antibody.
(B) Rheb induces constitutive 4E-BP1 phosphorylation in the absence of insulin. HA-4E-BP1 was expressed alone in HEK 293 cells alone or
together with myc-Rheb, and the extent of 4E-BP1 phosphorylation was monitored with a phosphospecific antibody following no treatment
or following stimulation with 200 nM insulin as indicated.
(C) Basal- and insulin-stimulated PKB phosphorylation is inhibited by Rheb. HA-PKB was expressed in HEK 293 cells alone or together with
myc-Rheb, and the extent of PKB phosphorylation was monitored with a phosphospecific antibody following no treatment or following
stimulation with 200 nM insulin as indicated.
(D) Insulin-induced activation of S6K1 is inhibited in HeLa cells when Rheb levels are decreased by RNAi. Cells were cotransfected with a
myc-S6K1-GST reporter alone or together with the indicated Rheb siRNAs (R215 or R177) or with a control siRNA. After stimulation with 200
nM insulin, S6K1 phosphorylation was monitored with a phosphospecific antibody.
was previously observed in TSC2/ MEFs (Jaeschke relieving TSC1/2 inhibition of Rheb, and that the effects
of amino acid and energy on mTOR function are regu-et al., 2002). These findings are consistent with the re-
pressive effects of TSC1/2 on S6K1 activation being lated by distinct mechanisms.
If the severest forms of TSC syndrome are associatedrelieved by insulin-induced activation of PI3K. It has
also been demonstrated that S6K1 activation in TSC1/ with mutations that affect the TSC2 GAP domain, then
mutations in this domain associated with the disease2-deficient cells is resistant to amino acid deprivation.
Both amino acids and ATP affect the mTOR pathway, should be ineffective in suppressing both Rheb activa-
tion and Rheb-induced activation of the mTOR/S6K/with the effects of amino acids being indirect and those
of ATP being direct on mTOR (Dennis et al., 2001). Con- 4E-BP signaling pathway. To test this possibility, we
analyzed the effect of one such human mutation harbor-sistent with these findings, amino acid withdrawal has
no negative impact on Rheb-induced S6K1 activation; ing a single amino acid change in the TSC2 GAP domain,
N1643K, on both responses. Although, coexpression ofindeed, it consistently leads to a slight stimulation,
whereas insulin-induced activation is totally abolished wild-type TSC1/2-GAP lowers the amount of GTP bound
Rheb, similar to the result depicted in Figure 1C, a TSC1/(Figure 4A). Consistent with the inhibitory effects of
2-deoxyglucose (2-DG) on mTOR being attributed to its 2-GAP mutant harboring a point mutation in the GAP
domain, N1643K, had no effect on the levels of GTPlowering of intracellular ATP levels (Dennis et al., 2001),
which act directly on mTOR, 2-DG almost totally abol- bound Rheb (Figure 4B). Likewise, coexpression of the
wild-type TSC2, but not the TSC2 GAP mutant, blockedishes Rheb-induced S6K1 activation, almost to the same
extent as rapamycin (Figures 4A). The results support Rheb-induced S6K1 activation (Figure 4C). These find-
ings are consistent with loss of TSC1/2-GAP functiona model whereby insulin-induced PI3K activation is in
part responsible for mediating S6K1 activation through leading to increase in GTP bound Rheb and driving pro-
Molecular Cell
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Figure 4. Effect of Pharmacological Agents, Amino Acid Deprivation, and a TSC2 Mutant on Rheb-Induced S6K1 Activation
(A) HeLa cells were transfected with myc-S6K1-GST alone or together with myc epitope-tagged Rheb and then deprived of serum overnight.
Cells were then pretreated with either 100 nM wortmannin, 20 nM rapamycin, or 100 mM 2-DG for 15 min or deprived of amino acids for 15
min and then stimulated with 200 nM insulin for 30 min. S6K1 phosphorylation was monitored with a phosphospecific antibody.
(B) A TSC syndrome-related GAP mutant of TSC2 fails to inhibit Rheb activity. Myc-Rheb was transfected alone into COS-7 cells or together
with HA-TSC1 and either wild-type Flag-TSC2 or Flag-TSC2 harboring a point mutation, N1643K, in the GAP domain.
(C) A TSC syndrome-related GAP mutant of TSC2 fails to inhibit Rheb-induced S6K1 phosphorylation. Transfections were performed as in
(B), except that myc-S6K1-GST was used as a reporter and the experiment was conducted in HeLa cells. S6K1 phosphorylation was monitored
with a phosphospecific antibody.
liferation through activation of the mTOR/S6K/4E-BP larvae represses dS6K activity, whereas larvae harbor-
ing mutations in dTsc1 or 2 or Drosophila cultured cellssignal transduction pathway.
treated with dTsc1 or 2 double-stranded RNAi have in-
creased dS6K activity (Gao et al., 2002; Radimerski etDiscussion
al., 2002). In parallel, similar results were found in mam-
malian systems (Goncharova et al., 2002; Inoki et al.,The finding that TSC1/2 is a negative effector of the
2002; Jaeschke et al., 2002; Manning et al., 2002; TeemTOR/S6K/4E-BP signal transduction pathway emerged
et al., 2002). Here we show that in mammalian cells thefrom studies in Drosophila, demonstrating that dS6K
target of TSC1/2 is the small GTPase Rheb. During thewas epistatic to the dTsc1/2, the Drosophila orthologs
time these studies were being carried out, we also identi-of TSC1/2 (Gao and Pan, 2001; Potter et al., 2001; Tapon
fied mutations in the Drosophila ortholog of Rheb,et al., 2001). Recent biochemical studies have confirmed
the epistatic relationship; overexpression of dTsc1/2 in dRheb, while carrying out a genome-wide screen in
TSC1/2: A GAP for the Small GTPase Rheb
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search of new effectors of growth. Such mutants were pronounced effect on S6K1 activity (Dennis et al., 2001).
In subsequent studies, we have not been able to detectfound to strongly suppress growth and to totally abolish
the overgrowth phenotype induced by dTsc1/2 loss-of- any effects of coexpressing TSC1/2 on mTOR in vitro
kinase activity, although such treatment blocks reporterfunction mutations. In contrast, overexpression of dRheb
induces overgrowth, an effect that is strongly suppressed S6K1 activation (S.Y. Kim and G.T., unpublished data).
In addition, recent studies have shown that mTOR existsin a dS6K-deficient background. Consistent with the
findings reported here, larvae harboring mutations in in multienzyme complexes and directly interacts with at
least two additional proteins, raptor and mLST8, whichdRheb or larvae overexpressing dRheb have either re-
duced or elevated dS6K activity, respectively (Stocker mediate its ability to signal to downstream substrates
such as S6K1 and 4E-BP1 (Hara et al., 2002; Kim et al.,et al., 2003). Here we show in mammalian cells, as is
presumably the case in Drosophila, that these effects 2002; Loewith et al., 2002; Nojima et al., 2003). This
raises the possibility that Rheb, rather than being a directare controlled through modulating Rheb GTPase activ-
ity. Our results are fully consistent with TSC2 acting activator of mTOR, may have a more permissive role,
acting instead on one of the proteins, which interactas a GAP for Rheb, although in vitro experiments with
bacterially produced proteins are required to confirm with mTOR. The identification of the downstream Rheb
effector will be essential in further elucidating the molec-this. Moreover, we show that insulin-induced activation
of Rheb mediates activation of the mTOR/S6K/4E-BP ular mechanisms by which this pathway is controlled.
The finding that Rheb is largely in the GTP boundsignal transduction pathway, in a PI3K-dependent man-
ner (Figures 2A and 3D). active state in TSC2-deficient cells is consistent with
Rheb mediating the pathological effects caused by mu-The question that arises from these studies is the mech-
anism by which GTP bound Rheb stimulates the mTOR/ tations in TSC1 and 2. In this respect, it should be noted
that the Rheb gene has been mapped to chromosomeS6K/4E-BP signal transduction pathway. The fact that
dTsc2 and dTOR were found to coimmunoprecipitate 7q36 (Mizuki et al., 1996), a locus that has been impli-
cated through positional cloning to contain one or morewith one another when overexpressed in Drosophila-
cultured cells (Gao et al., 2002) and that coexpression susceptibility genes for autism (International Molecular
Genetic Study of Autism Consortium, 1998). Moreover,of TSC1/2 with mTOR in mammalian cells was found to
block mTOR kinase activity in an immune-complex 20%–30% of patients who present TSC syndrome have
no mutations in TSC1 or 2 (D. Franz, personal communi-assay in vitro employing S6K1 as a substrate (Inoki et
al., 2002) suggested that the target of TSC1/2 inhibition cation), raising the possibility that mutations in Rheb or
its overexpression could be responsible for the diseasewas mTOR. This conclusion was also supported by the
fact that a second kinase target of mTOR, 4E-BP1 (Brunn in these patients. Ras family members contain five re-
gions involved in GTP binding, denoted G1 through G5et al., 1997; Gingras et al., 1998), is also constitutively
phosphorylated in TSC2/ cells (Jaeschke et al., 2002), (Bourne et al., 1990). These regions contain the highest
shared homologies between Ras and Rheb, and areand overexpression of TSC1/2 inhibited this response
(Inoki et al., 2002). Most importantly, insulin activation consistent with the intrinsic GTPase activity of Rheb
(Yamagata et al., 1994). One of the most striking featuresof an S6K1 variant, which is decoupled from mTOR, was
not suppressed by coexpression of TSC1/2 (Inoki et al., of Rheb is the G1 box, or the GX4GKS/T motif, where
Rheb encodes arginine and serine at positions 15 and2002). This variant lacks both the carboxy autoinhibitory
domain and the acidic amino terminus and is rapamycin 16, rather than the glycines that are present at the ho-
mologous sites in the other Ras family members (Bos,resistant (Cheatham et al., 1995; Dennis et al., 1996;
Weng et al., 1995). Such mutants have been exploited 1997; Reuther and Der, 2000). The arginine may be par-
ticularly important, since an equivalent mutation in Rasto show that amino acids (Hara et al., 1998) or ATP
(Dennis et al., 2001) act either upstream of or directly on results in low intrinsic GTPase activity and resistance
to the GTPase-activating effects of Ras-GAP (Bos, 1997;mTOR, respectively. The studies presented here would
support a model whereby the inhibitory affects of TSC1/2 Reuther and Der, 2000). However, the results presented
here argue that TSC1/2 can stimulate the GTPase activ-on mTOR are mediated through inhibition of Rheb, which
in turn acts as an activator of mTOR. ity of Rheb. In this respect it is interesting to note that
TSC2-GAP is a close relative of Rap1-GAP, which in-However, despite the observations above, the point at
which TSC1/2 acts in the mTOR pathway is controversial duces GTPase activity of Rap1 by a different mechanism
than Ras-GAP induces the GTPase activity of Ras (Brink-(McManus and Alessi, 2002). First, activation of a second
S6K1 variant, which is also decoupled from mTOR, is mann et al., 2002). Similar to Rheb, Rap1 has a T rather
than the common Q in the DTAGQE motif of the G3 box,still suppressed by coexpression of TSC1/2 (Jaeschke
et al., 2002). This variant also lacks the carboxy autoin- resulting in very low intrinsic GTPase activity. In fact, a
similar mutation in Ras makes it resistant to Ras-GAPhibitory domain but has glutathion transferase fused to
its intact amino terminus and is also resistant to rapa- (Brinkmann et al., 2002).
Rheb is in a high activation state when it is overex-mycin (Dennis et al., 2001). Moreover, the ability to de-
tect changes in mTOR activity in vitro following mitogen pressed at low levels (Im et al., 2002; data not shown),
possibly overcoming endogenous levels of TSC1/2-GAP.treatment has been difficult to demonstrate (Dennis et
al., 2001; Gingras et al., 2001; Kim et al., 2002). Indeed, In agreement with this notion, we did not find any sub-
stantial regulation of transfected Rheb by insulin, aminowe reported earlier, employing the same assay as Inoki
et al. (2002), that we were unable to detect changes in acid depletion, serum starvation, or wortmannin treat-
ment (data not shown). Notably, Rheb overexpressionmTOR activity as a function of either stimulation of cells
with insulin or by ectopic expression of activated alleles has been detected in a number of tumor cell lines (Gro-
mov et al., 1995), and overexpression of wild-type Rhebof PI3K, despite the fact that both treatments have a
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Radioactive Activation Assay for Small GTPasesis as efficient as wild-type Raf-1 or H-Ras in inducing
Measurements of GTP/GDP-charged state of transfected epitope-transformation in NIH3T3 cells (Yee and Worley, 1997).
tagged small GTPases were performed as described earlier (Wol-Furthermore Rheb strongly synergizes with Raf-1, to the
thuis et al., 1997), except that overexpressed Rheb was pulled down
same extent as Raf-1 synergizes with wild-type H-Ras, with anti-myc antibody. For measurements of endogenous Rheb
in the NIH 3T3 transformation assay (Yee and Worley, and Ras activities, the proteins were pulled down by either the C19
or Y13-259 antibody, respectively.1997). A similar effect as overexpression can be ex-
pected from mutations that render Rheb insensitive to
AcknowledgmentsTSC2, like the F64A mutation in Rap1 that makes Rap1
resistant to Rap1GAP (Brinkmann et al., 2002). However,
We are grateful to D. Kwiatkowski for providing TSC2/ and
such mutations have not been reported in patients. At TSC2/ MEFs, J. Sampson for the TSC2 GAP N1643K mutant, F.
this point it will be important to determine whether (1) Nett and S. Gfeller for providing technical advice, P.D. Dennis for
his critical reading of the manuscript, and S.-Y. Kim and J. EnserinkRheb is overexpressed or contains mutations in TSC
for their help and discussions. We also thank F. Zilbermann forsyndrome patients, which have no mutations in TSC1
technical assistance. Finally, we are indebted to S. Oakeley, E. Oake-or 2, (2) it represents a susceptibility locus for autism,
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recipients of EMBO Long-Term and Swiss Cancer League Fellow-
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